From putative brain tumor marker to high cognitive abilities: Emerging roles of a disintegrin and metalloprotease (ADAM) 12 in the brain
- 1 November 2020
- journal article
- review article
- Published by Elsevier in Journal of Chemical Neuroanatomy
- Vol. 109, 101846
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Perineuronal oligodendrocytes in health and disease: the journey so farReviews in the Neurosciences, 2019
- Identification of ADAM12 as a Novel Basigin SheddaseInternational Journal of Molecular Sciences, 2019
- The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitisActa Neuropathologica, 2019
- Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapySchizophrenia Research, 2015
- NF-κB signaling regulates myelination in the CNSFrontiers in Molecular Neuroscience, 2014
- Concerning HB ‐ EGF Brain Levels in Schizophrenia: Cellular Distribution of Putative Sheddases May MatterCNS Neuroscience & Therapeutics, 2012
- ADAM12 is expressed by astrocytes during experimental demyelinationBrain Research, 2010
- Genome-wide Association Study Implicates a Chromosome 12 Risk Locus for Late-Onset Alzheimer DiseaseThe American Journal of Human Genetics, 2009
- ADAM (a disintegrin and metalloprotease) 12 is expressed in rat and human brain and localized to oligodendrocytesJournal of Neuroscience Research, 2003
- Regional and cellular distribution of neural visinin-like protein immunoreactivities (VILIP-1 and VILIP-3) in human brainJournal of Neurocytology, 1999